Results 71 to 80 of about 4,767 (196)

Development of the drug oncolytic immunotherapy based on vaccinia viruses (Vaccinia virus, Orthopoxvirus, Chordopoxvirinae, Poxviridae) against breast cancer

Вопросы вирусологии, 2020
Introduction. Currently, new directions in cancer therapy are actively developing, one of which is oncolytic immunotherapy. This approach would be to use of viruses as cancer specific cytolytic agents capable of stimulating both the tumor-specific and ...
T. V. Bauer, T. V. Tregubchak, A. Z. Maksyutov, R. A. Maksyutov, I. V. Kolosova, E. V. Gavrilova   +5 more
doaj   +1 more source

Oncolytic vaccinia virus demonstrates antiangiogenic effects mediated by targeting of VEGF [PDF]

International Journal of Cancer, 2014
Oncolytic vaccinia virus has been shown to induce a profound, rapid and tumor‐specific vascular collapse in both preclinical models and clinical studies; however, a complete examination of the kinetics and levels of collapse and revascularization has not been described previously.
Weizhou, Hou, Hannah, Chen, Juan, Rojas, Padma, Sampath, Stephen H, Thorne   +4 more
openaire   +2 more sources

Integrating Oncolytic Virus Engineering and Delivery Strategies for Enhanced Cancer Virotherapy

Aggregate, Volume 7, Issue 6, June 2026.
Integrated engineering strategies combining oncolytic virus (OV) design with advanced delivery platforms overcome biological barriers and enhance cancer virotherapy. Genetic engineering improves viral potency and selectivity, while local and systemic delivery systems promote viral protection, tumor targeting, penetration, and tumor microenvironment ...
Jiliang Zhao, Dong Wang, Lei Wang, Hongkai Zhang, Yue Sun, Dan Ding   +5 more
wiley   +1 more source

Therapeutic Poxviruses Induce the Secretion of Immunostimulating and Anti‐Tumoral Extracellular Vesicles

Journal of Extracellular Vesicles, Volume 15, Issue 6, June 2026.
Immune cells infected by therapeutic poxviruses release increased amounts of extracellular vesicles bearing viral proteins and therapeutic payloads. Such EVs have the ability to activate a CD8+ T‐cell mediated antitumoral immune response and decrease tumor growth.
Lucas Walther, Vincent Mittelheisser, Marie‐Christine Claudepierre, Louis Bochler, Magali Rompais, Jules Deforges, Nathalie Silvestre, Annabel Larnicol, Christine Carapito, Eric Quémeneur, Jacky G Goetz, Karola Rittner, Vincent Hyenne   +12 more
wiley   +1 more source

Evaluation of the effects of oncolytic vaccinia virus on colorectal liver metastases in cell lines and in organotypic cultures.

, 2019
Vaccinia virus is one of several live viruses currently being evaluated in clinical trials as cancer therapies. One oncolytic virus, T-VEC, is already in clinical use and is NICE approved for the treatment of melanoma.
Kostalas, Marcos
core   +1 more source

Tumor vascularization is critical for oncolytic vaccinia virus treatment of peritoneal carcinomatosis [PDF]

International Journal of Cancer, 2013
Peritoneal carcinomatosis (PC) represents a significant clinical challenge for which there are few treatment options. Oncolytic viruses are ideal candidates for PC treatment because of their high tumor specificity, excellent safety profile and suitability for peritoneal delivery.
Kathryn, Ottolino-Perry, Nan, Tang, Renee, Head, Calvin, Ng, Rozanne, Arulanandam, Fernando A, Angarita, Sergio A, Acuna, Yonghong, Chen, John, Bell, Ralph S, Dacosta, J Andrea, McCart   +10 more
openaire   +2 more sources

Organoids: From Bench to Bedside Applications

MedComm, Volume 7, Issue 6, June 2026.
Organoids, as a groundbreaking biomedical research platform, utilize adult stem cells (ASCs), embryonic stem cells (ESCs), and induced pluripotent stem cells (iPSCs) as sources. By integrating specific growth and differentiation signals within an extracellular matrix (e.g., Matrigel), organoids guide cells to self‐assemble into three‐dimensional ...
Kelin Li, Rui Cao, Maochen Li, Zichao Tian, Huahao Fan, Bixia Hong, Xiaojuan Liu   +6 more
wiley   +1 more source

IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy

Journal for ImmunoTherapy of Cancer, 2021
Background Oncolytic viruses (OVs) have shown promise in containing cancer progression in both animal models and clinical trials. How to further improve the efficacy of OVs are intensively explored.
Xiaoyan Zhang, Chen Zhao, Tianyue Chen, Xiangqing Ding, Qibin Liao, Nan Gao, Jianqing Xu   +6 more
doaj   +1 more source

The Expanding Landscape of Microbiota Medicine: Indications, Therapeutic Modalities, and the Path Towards Integrative Microbiome‐Targeting Healthcare

Microbiota Medicine Research, Volume 1, Issue 2, Page 63-89, June 2026.
ABSTRACT The growing recognition of the microbiome’s role in human health has propelled the emergence of microbiota medicine—a new discipline integrating microbiology, multi‐omics, and clinical science. Advances in sequencing, data integration, and interventions such as fecal microbiota transplantation (FMT) have transitioned the field from ...
Min Dai, Yisha Lin, Renyou Gan, Xiaotao Shen, Shin Young Park, Sunjae Lee, Qi Su   +6 more
wiley   +1 more source

High oncolytic activity of a double deleted Vaccinia Virus Copenhagen strain against malignant pleural mesothelioma: Mesothelioma and oncolytic vaccinia virus

, 2020
International audienceMalignant pleural mesothelioma (MPM) is a cancer of the pleura that lacks efficient treatment. Oncolytic immunotherapy using oncolytic vaccinia virus (VV) may represent an alternative therapeutic approach for the treatment of this ...
Delaunay, Tiphaine, Erbs, Philippe, Farine, Isabelle, Pouliquen, Daniel, L., Hedwig, Vera, Fonteneau, Jean-François, Grard, Marion, Blondy, Thibaut, Boisgerault, Nicolas, Violland, Mathilde, Foloppe, Johann, Nader, Joëlle, Grégoire, Marc   +12 more
core   +1 more source